

ImmunityBio™



# Jefferies Healthcare Conference Presentation

June 7, 2023

# Forward Looking Statements

This presentation and the accompanying verbal remarks contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the development of therapeutics for cancers and infectious diseases and related business strategies, potential regulatory pathway for certain of ImmunityBio's product candidates and target indications, data from the clinical trials for certain of ImmunityBio's product candidates, clinical trial enrollment and results, clinical trial design and protocols, the regulatory review process and timing thereof, timing of regulatory submissions, potential implications to be drawn from clinical trials, potential commercialization of product candidates, and ImmunityBio's product candidates as compared to existing treatment options, among others. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as "anticipates," "believes," "continues," "goal," "could," "estimates," "scheduled," "expects," "intends," "may," "plans," "potential," "predicts," "indicate," "projects," "seeks," "should," "will," "strategy," and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) the risks and uncertainties associated with the regulatory submission, review and approval process, (ii) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs, and the timing and success of any such continued preclinical and clinical development and planned regulatory submissions, (iii) ImmunityBio's ability to retain and hire key personnel, (iv) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (v) ImmunityBio's ability to successfully commercialize its product candidates and uncertainties around regulatory reviews and approvals, (vi) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its product candidates and future approved products, (vii) ImmunityBio's ability to obtain, maintain, protect and enforce patent protection and other proprietary rights for its product candidates and technologies, and (viii) the unknown future impact of the COVID-19 pandemic on certain clinical trials or their milestones and/or ImmunityBio's business operations or operating expenses. More details about these and other risks that may impact ImmunityBio's business are described under the heading "Risk Factors" in the Company's Form 10-Q filed with the U.S. Securities and Exchange Commission ("SEC") on May 11, 2023, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at www.sec.gov. ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this presentation, except to the extent required by law.

# N-803 (Anktiva) First-in-Class IL-15 Superagonist Induces Proliferation and Activation of NK, T Cells and Memory T Cells

Memory T Cells Resulting in Duration of Complete Response > 24 Months

**BCG Unresponsive NMIBC**

**QUILT 3032**




**BCG + IL-15 Administered Intravesicalily**


**BCG**

+

**N-803 (NAI) Anktiva**

**Infected Cell** → **Stressed Cell Expressing Ligands for NK & T Cell** → **N-803 (IL-15) Recruiting NK & T Cells** → **Activation of NK & T Cells to Infected Cell** → **Immunogenic Cell Death**







**N-803 Expanded & Activated NK & T Cells**

**Long Term Memory**

**Durable Complete Remission**

26.6 Month Median Duration of Response
95% CI: Higher Bound Not Reached
(Updated Data to Date)




# ImmunityBio: The Cancer Vaccine Company

Expanding the Treatment Options From Preventing Metastasis to Preventing Cancer




**Elements of the Cancer, COVID, and HIV Vaccines**



**Immuno-Modulator**
- DAMP Inducers
- Aldoxorubicin
- Nanatinostat



**Natural Killer Cells**
- PD-L1 t-haNK
- CD-19 t-haNK
- M-ceNK



**Dendritic Cell Activator**
- Adenovirus
- Yeast
- saRNA / NLC
- Adjuvants (TLR7, TLR8)




**NK, T Cell, Memory Cell Activator**
- N-803: Interleukin 15 Superagonist



Agents listed here are investigational. Safety and efficacy have not been established by any Health Authority or Agency.

# ImmunityBio: The Cancer Vaccine Company

Expanding the Treatment Options From Preventing Metastasis to Preventing Cancer
From 3rd Line Disease or Greater to Newly Diagnosed Cancer to Prevention in Normal Subjects

| | *Metastatic/Advanced* | *Prevention of Metastasis* | *Prevention of Cancer* |
|---|---|---|---|
| Bladder | **BCG Unresponsive**<br>QUILT-3.032 (BLA Filed) | **BCG Naïve**<br>Actively Recruiting (QUILT-2.005) | |
| Colon | **3rd Line**<br>Completed (NCT01147965) | **Micro-Satellite Stable**<br>In Process (QUILT-208) | **Lynch Syndrome**<br>Actively Recruiting (NCT05419011) |
| Neoepitope All Tumors | | **1st Line**<br>Actively Recruiting (QUILT-2.025) | **Lynch Syndrome**<br>In Process (QUILT-211) |
| Pancreas | **2nd & 3rd Line Pancreatic**<br>Completed (QUILT-88) | **1st Line Neoadjuvant**<br>In Process (QUILT-206) | |
| Glioblastoma | **3rd Line**<br>Individual Patient (spIND) | **2nd Line**<br>IND Authorized (QUILT-3.078) | |
| Small Cell Lung | **3rd Line**<br>Completed (QUILT-3.055) | **2nd Line**<br>In Process (QUILT-209) | |
| Head & Neck | **3rd Line**<br>Completed (NCT04290546) | **1st Line Neoadjuvant**<br>In Process (QUILT-210) | |